This inventor holds 2 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignees: The United States of America, as Represented by the Secretary, Department of Health and Human Services, The University of North Carolina at Chapel Hill, University of Kansas. Active years: 2023-2024.
Company Filing History:
2 out of 3,693 
2 out of 1,326 
2 out of 572 
Years Active: 2023-2024
Title: Amy Elizabeth Moritz: Innovator in Dopamine Receptor Agonists
Introduction
Amy Elizabeth Moritz is a prominent inventor based in Bethesda, MD (US). She has made significant contributions to the field of pharmacology, particularly in the development of selective dopamine receptor agonists. Her work has implications for treating various neurodegenerative disorders and mental health conditions.
Latest Patents
Amy holds 2 patents related to her innovative research. Her latest patents include "Selective D3 dopamine receptor agonists and methods of their use" and "Selective D dopamine receptor agonists and methods of their use." These patents disclose compounds that can be used in treating conditions such as Parkinson's disease, Alzheimer's disease, and other related syndromes. The compounds are designed to be administered alongside pharmaceutically acceptable carriers, providing a comprehensive approach to treatment.
Career Highlights
Throughout her career, Amy has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the University of Kansas Medical Center Research Institute. Her experience in these institutions has allowed her to advance her research and contribute to significant medical advancements.
Collaborations
Amy has collaborated with notable professionals in her field, including David Robert Sibley and R Benjamin Free. These collaborations have enriched her research and expanded the impact of her work in the scientific community.
Conclusion
Amy Elizabeth Moritz is a trailblazer in the development of dopamine receptor agonists, with a focus on treating complex neurological and psychiatric disorders. Her patents and career achievements reflect her dedication to advancing medical science and improving patient outcomes.